← All trials
NCT05378893
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- May 18, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang Doer Biologics Co., Ltd.Lead sponsor
- New Zealand Clinical ResearchOverall official - principal investigator
- Zhejiang Doer Biologics Co., Ltd.Study chair
- Zhejiang Doer Biologics Co., Ltd.Study director
- Huadong Medicine Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.